WFM
TCRT icon

Wilmington Funds Management’s Alaunos Therapeutics TCRT Stock Holding History

Wilmington Funds Management’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		$42K Hold
69
– – ﹤0.01% 734
2014
Q1 		$48K Sell
69
-8
-10% -$5.36K 0.01% 753
2013
Q4 		$50K Buy
+77
New +$45.9K 0.01% 776
2013
Q3 		– Sell
-395
Closed -$124K – 789
2013
Q2 		$124K Buy
+395
New +$110K 0.01% 687

Other funds holding TCRT

TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
EWM
Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BGA
Belmont Global Advisors Dallas, Texas $106M AUM 2.89% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wilmington Funds Management's TCRT Position: Q2 2014 in Review

Wilmington Funds Management held its Alaunos Therapeutics (TCRT) position steady in Q2 2014 at 69 shares worth $42K. The position accounts for ﹤0.01% of the portfolio, ranked #734.

Wilmington Funds Management first reported a position in TCRT in Q2 2013 and has held it in 4 quarters since. The position peaked at $124K in Q2 2013. 92 funds tracked by Wall St. Rank hold TCRT as of Q2 2014.

  • Wilmington Funds Management held 69 shares of Alaunos Therapeutics worth $42K as of Q2 2014.
  • Wilmington Funds Management left its Alaunos Therapeutics share count unchanged in Q2 2014.
  • Alaunos Therapeutics made up ﹤0.01% of Wilmington Funds Management's portfolio in Q2 2014, its #734 holding.
  • Wilmington Funds Management first reported a position in Alaunos Therapeutics in Q2 2013 and has held it in 4 quarters since.
  • Wilmington Funds Management's Alaunos Therapeutics position peaked at $124K in Q2 2013.
  • 92 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q2 2014.

Based on Wilmington Funds Management's 13F filing for Q2 2014, filed 13 Aug 2014.